WO2014075203A1 - Nanopartículas con polímero biodegradable y biocompatible plga cargadas con el fármaco de uso humano pentoxfilina - Google Patents

Nanopartículas con polímero biodegradable y biocompatible plga cargadas con el fármaco de uso humano pentoxfilina Download PDF

Info

Publication number
WO2014075203A1
WO2014075203A1 PCT/CL2013/000084 CL2013000084W WO2014075203A1 WO 2014075203 A1 WO2014075203 A1 WO 2014075203A1 CL 2013000084 W CL2013000084 W CL 2013000084W WO 2014075203 A1 WO2014075203 A1 WO 2014075203A1
Authority
WO
WIPO (PCT)
Prior art keywords
loaded
nanoparticles
biodegradable
drug
biocompatible polymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CL2013/000084
Other languages
English (en)
French (fr)
Other versions
WO2014075203A8 (es
Inventor
Luis Ernesto CONSTANDIL CÓRDOVA
Paula Soledad IBARRA DURÁN
Cristian Andrées VILOS ORTÍZ
Luis VELÁSQUEZ CUMPLIDO
Teresa PELISSIER SERRANO
Claudio Aurelio LAURIDO FUENZALIDA
Alejandro HERNÁNDEZ KUNSTMANN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universidad de Santiago de Chile
Original Assignee
Universidad de Santiago de Chile
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universidad de Santiago de Chile filed Critical Universidad de Santiago de Chile
Priority to MX2015006187A priority Critical patent/MX2015006187A/es
Priority to BR112015011294A priority patent/BR112015011294A8/pt
Priority to US14/443,260 priority patent/US20150283095A1/en
Publication of WO2014075203A1 publication Critical patent/WO2014075203A1/es
Publication of WO2014075203A8 publication Critical patent/WO2014075203A8/es
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención describe una nueva formulación farmacéutica, que comprende nanopárticulas polímeras del polímero biodegradable y biocompatible ácido (lático glicólito) (PLGA) cargados con la droga pentoxifilina el método de síntesis de las nanopartículas de (PLGA) cargadas con pentoxifilina y el uso de ellas en el tratamiento efectivo del alivio del dolor crónico y para la prevención del dolor crónico mediante la administración de una dosis única.

Description

Figure imgf000003_0001
Figure imgf000004_0001
Figure imgf000005_0001
Figure imgf000006_0001
Figure imgf000007_0001
Figure imgf000008_0001
Figure imgf000009_0001
Figure imgf000010_0001
Figure imgf000011_0001
Figure imgf000012_0001
Figure imgf000013_0001
Figure imgf000014_0001
Figure imgf000015_0001
Figure imgf000016_0001
Figure imgf000017_0001
Figure imgf000018_0001
Figure imgf000019_0001
Figure imgf000020_0001
Figure imgf000021_0001
Figure imgf000022_0001
Figure imgf000023_0001
Figure imgf000024_0001
Figure imgf000025_0001
Figure imgf000026_0001
Figure imgf000027_0001
Figure imgf000028_0001
Figure imgf000029_0001
Figure imgf000030_0001
Figure imgf000031_0001
Figure imgf000032_0001
Figure imgf000033_0001
Figure imgf000034_0001
Figure imgf000035_0001
Figure imgf000036_0001
Figure imgf000037_0001
Figure imgf000038_0001
Figure imgf000039_0001
Figure imgf000040_0001
Figure imgf000041_0001
Figure imgf000042_0001
Figure imgf000043_0001
Figure imgf000044_0001
Figure imgf000045_0001
Figure imgf000046_0001
w mu? i-fin
Figure imgf000047_0001
Figure imgf000048_0001

Claims

Figure imgf000049_0001
Figure imgf000050_0001
Figure imgf000051_0001
Figure imgf000052_0001
Figure imgf000053_0001
Figure imgf000054_0001
PCT/CL2013/000084 2012-11-16 2013-11-15 Nanopartículas con polímero biodegradable y biocompatible plga cargadas con el fármaco de uso humano pentoxfilina Ceased WO2014075203A1 (es)

Priority Applications (3)

Application Number Priority Date Filing Date Title
MX2015006187A MX2015006187A (es) 2012-11-16 2013-11-15 Nanoparticulas con polimero biodegradable y biocompatible acido poli(lactico-glicolico)(plga) cargadas con el farmaco de uso humano pentoxifilina.
BR112015011294A BR112015011294A8 (pt) 2012-11-16 2013-11-15 nanopartículas com polímero biodegradável e biocompatível plga carregadas com o fármaco pentoxifilina de uso humano e uso destas
US14/443,260 US20150283095A1 (en) 2012-11-16 2013-11-15 Nanoparticles with biodegradable and biocompatible polymer plga, loaded with the drug for human use pentoxifylline

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CL2012003209A CL2012003209A1 (es) 2012-11-16 2012-11-16 Metodo de sintesis de nanoparticulas de acido poli (lactico-glicolico) (plga) con pentoxifilina; composicion farmaceutica que comprende nanoparticulas de plga con pentoxifilina; y uso de las nanoparticulas de plga cargada con pentoxifilina en el tratamiento del alivio y prevencion del dolor cronico.
CL3209-2012 2012-11-16

Publications (2)

Publication Number Publication Date
WO2014075203A1 true WO2014075203A1 (es) 2014-05-22
WO2014075203A8 WO2014075203A8 (es) 2014-07-17

Family

ID=50730445

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CL2013/000084 Ceased WO2014075203A1 (es) 2012-11-16 2013-11-15 Nanopartículas con polímero biodegradable y biocompatible plga cargadas con el fármaco de uso humano pentoxfilina

Country Status (5)

Country Link
US (1) US20150283095A1 (es)
BR (1) BR112015011294A8 (es)
CL (1) CL2012003209A1 (es)
MX (1) MX2015006187A (es)
WO (1) WO2014075203A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8153435B1 (en) 2005-03-30 2012-04-10 Tracer Detection Technology Corp. Methods and articles for identifying objects using encapsulated perfluorocarbon tracers
EP4408400A4 (en) * 2021-09-29 2025-08-06 Oncour Pharma Inc NEGATIVELY CHARGED PARTICLES FOR THE TREATMENT OF BURNS ASSOCIATED WITH INFLAMMATION
CN114870023A (zh) * 2022-05-12 2022-08-09 成都市第三人民医院 一种缓释的视神经保护药物纳米合成材料及其制备方法和应用
CN116585488B (zh) * 2023-05-08 2024-02-23 广东省第二人民医院（广东省卫生应急医院） 一种罗哌卡因纳米载药材料及其制备方法
CN116869968B (zh) * 2023-09-07 2023-11-24 四川大学 一种靶向大脑和脑胶质瘤的纳米粒及其合成方法、应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995019174A1 (en) * 1994-01-18 1995-07-20 Alza Corporation Pentoxifylline dosage form
WO2008054042A1 (en) * 2006-11-01 2008-05-08 Jae Woon Nah Bio-degradable nanoparticles of poly(dl-lactide-co-glycolide) encapsulating ciprofloxacin hcl having an extended-release property, and manufacturing method thereof
US20090263491A1 (en) * 2006-03-24 2009-10-22 Lts Lohmann Therapie-Systeme Ag Polylactide Nanoparticles

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2648099C (en) * 2006-03-31 2012-05-29 The Brigham And Women's Hospital, Inc System for targeted delivery of therapeutic agents
WO2012037093A1 (en) * 2010-09-13 2012-03-22 Tenera Therapeutics, Llc Compositions for treating cancer treatment - related fatigue
CN104684546A (zh) * 2012-06-07 2015-06-03 哈佛大学校长及研究员协会 用于药物靶向的纳米疗法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995019174A1 (en) * 1994-01-18 1995-07-20 Alza Corporation Pentoxifylline dosage form
US20090263491A1 (en) * 2006-03-24 2009-10-22 Lts Lohmann Therapie-Systeme Ag Polylactide Nanoparticles
WO2008054042A1 (en) * 2006-11-01 2008-05-08 Jae Woon Nah Bio-degradable nanoparticles of poly(dl-lactide-co-glycolide) encapsulating ciprofloxacin hcl having an extended-release property, and manufacturing method thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
VARSHOSAZ JALEH ET AL.: "Enhancement of oral bioavailability of pentoxifylline by solid lipid nanoparticles.", JOURNAL OF LIPOSOME RESEARCH, vol. 20, no. 2, June 2010 (2010-06-01), pages 115 - 123, ISSN: 0898-2104 *

Also Published As

Publication number Publication date
WO2014075203A8 (es) 2014-07-17
CL2012003209A1 (es) 2013-04-19
US20150283095A1 (en) 2015-10-08
MX2015006187A (es) 2015-08-10
BR112015011294A2 (pt) 2017-07-11
BR112015011294A8 (pt) 2019-10-22

Similar Documents

Publication Publication Date Title
Vecsernyés et al. Cyclodextrins, blood–brain barrier, and treatment of neurological diseases
Irache et al. Nanomedicine: novel approaches in human and veterinary therapeutics
Giger et al. Biomedical applications of bisphosphonates
Pham et al. Strategies for the design of orally bioavailable antileishmanial treatments
CY1119805T1 (el) Συστημα χορηγησης φαρμακων για τη χορηγηση πτωχως υδατοδιαλυτων φαρμακευτικως ενεργων ουσιων
MX2021004546A (es) Composiciones de suministro de farmaco implantables y metodos de uso de las mismas.
PH12014502058A1 (en) Pharmaceutical composition comprising empagliflozin and antiobesity drug
EP3861982A3 (en) Intracameral implant for treatment of an ocular condition
NZ708506A (en) Methods of treating bladder cancer
NZ727975A (en) Compositions comprising electrohydrodynamically obtained fibres for administration of specific dosages of an active substance to skin or mucosa
EP3300734A3 (en) Use of levocetirizine and montelukast in the treatment of autoimmune disorders
EP2392363A3 (en) Drug coated expandable devices
NZ605469A (en) Nalbuphine-based formulations and uses thereof
NZ715686A (en) Pharmaceutical for oral delivery comprising mgbg and methods of treating disease
WO2014075203A1 (es) Nanopartículas con polímero biodegradable y biocompatible plga cargadas con el fármaco de uso humano pentoxfilina
WO2009148777A3 (en) Implantable drug delivery devices having alternating hydrophilic and amphiphilic polymer layers
MX365688B (es) Sistemas de administracion de farmaco y metodos para el tratamiento del cancer de vejiga que comprenden oxaliplatino.
MX2013014461A (es) Formulaciones de liberacion sostenida para el suministro de proteinas al ojo y metodos para prepararlas.
WO2014164285A3 (en) Use of levocetirizine and montelukast in the treatment of vasculitis
EA202090637A1 (ru) Способы применения дипивефрина
EA201391689A1 (ru) Система доставки лекарственного средства
EP4400165A3 (en) Vaginal drug delivery device
CO7101247A2 (es) Formulaciones de ácido poliinosínico-policitidílico (poli(i:c)) para el tratamiento de infecciones de las vías respiratorias altas
HK1213824A1 (zh) 治疗在糖尿病患者的血管疾病的方法
WO2016040814A3 (en) Disulfide polymers and methods of use

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13854787

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 14443260

Country of ref document: US

Ref document number: MX/A/2015/006187

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112015011294

Country of ref document: BR

122 Ep: pct application non-entry in european phase

Ref document number: 13854787

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 112015011294

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20150515